With no competing bids on the table, Valeant Pharmaceuticals International Inc. (NYSE:VRX) raised its unsolicited takeover offer for the second time this week for Allergan Inc to $53.8 billion on condition that the Botox maker agrees to talk on a merger. Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) net profit margin is -13.10% and weekly performance is 0.29%. On last trading day company shares ended up $131.21. Analysts mean target price for the company is $52.38. Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) distance from 50-day simple moving average (SMA50) is 1.10%.
Alkermes Plc (NASDAQ:ALKS) SVP Rebecca Peterson sold 21,981 shares of the stock in a transaction dated Friday, May 30th. The stock was sold at an average price of $45.86, for a total value of $1,008,048.66. Alkermes Plc (NASDAQ:ALKS) shares fell -0.59% in last trading session and ended the day on $45.81. ALKS gross Margin is 69.40% and its return on assets is 1.40%.Alkermes Plc (NASDAQ:ALKS) quarterly performance is -5.88%.
Flamel Technologies S.A. (ADR) (NASDAQ:FLML) on 12 may reported total revenues during the first quarter of 2014 of $9.2 million, which reflected the initial recognition of sales of Bloxiverz, compared to $5.1 million in the first quarter of 2013, an increase of 78.5% compared to the year-ago period. Product sales and services revenues in the first quarter of 2014 of were $5.9 million, compared to $2.1 million in the prior year quarter as the Company continues its successful transition from a drug delivery company to a self-funded specialty pharmaceutical company. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) shares moved up 0.63% in last trading session and was closed at $11.18, while trading in range of $10.59 – $11.19. Flamel Technologies S.A. (ADR) (NASDAQ:FLML) year to date (YTD) performance is 38.88%.
Intellipharmaceutics International Inc. (NASDAQ:IPCI) a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, on 20 may announced that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in each of the provinces and territories of Canada, except Quebec, and filed a registration statement with the United States Securities and Exchange Commission on Form F-3. IntelliPharmaCeutics Intl Inc. (USA) (NASDAQ:IPCI) ended the last trading day at $3.78. Company weekly volatility is calculated as 5.32% and price to cash ratio as 15.73.IntelliPharmaCeutics Intl Inc. (USA) (NASDAQ:IPCI) showed a positive weekly performance of 0.53%.
At the 2014 Annual Meeting of Stockholders of Columbia Laboratories, Inc. (NASDAQ:CBRX), held on May 8, 2014, three proposals were submitted to and approved by the stockholders. The proposals are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on March 31, 2014. Columbia Laboratories Inc. (NASDAQ:CBRX) net profit margin is 23.50% and weekly performance is 1.83%. On last trading day company shares ended up $6.67. Analysts mean target price for the company is $10.00. Columbia Laboratories Inc. (NASDAQ:CBRX) distance from 50-day simple moving average (SMA50) is -1.69%.